ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,354.05
0.49%
Dow Jones
39,056.39
0.44%
Gold vs US Dollar
2,312.39
0.18%
Brent Oil
83.755
0.23%
Bitcoin
61,625.97
0.72%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pharming Group NV (PHAR)

  7. Pharming Group NV (PHAR) News

Pharming Group NV (PHAR)

Pharming Group NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHAR
DateTimeSourceHeadlineSymbolCompany
08/05/202411:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
08/01/202414:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
26/10/202314:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202307:00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202306:00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202306:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
09/08/202306:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202316:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
03/08/202306:00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202306:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
18/07/202306:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202307:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
13/07/202307:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202311:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202306:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
01/06/202306:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202307:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
25/05/202307:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202316:28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202306:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
11/05/202306:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202307:00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202307:00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202306:36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202312:11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202313:58Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
11/04/202306:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202306:00PR Newswire (Canada)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202306:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
05/04/202311:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR

Your Recent History

LSE
ALBA
Alba Mineral Resources
LSE
GGP
Greatland Gold
LSE
SCE
Surface Transforms
LSE
GKP
Gulf Keystone Petroleum
LSE
CEG
Challenger Energy
LSE
INSP
Inspirit Energy
LSE
BIRD
Blackbird
LSE
JEMA
Jpmorgan Emerging Europe...
LSE
IGR
Ig Design
LSE
EDEN
Eden Research
LSE
RBG
Revolution Bars
LSE
TRP
Tower Resources
LSE
NIOX
Niox
LSE
AT.
Ashtead Technology
LSE
ENET
Ethernity Networks
LSE
BUR
Burford Capital
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved